754,822 Shares in BlackRock Health Sciences Term Trust (NYSE:BMEZ) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in shares of BlackRock Health Sciences Term Trust (NYSE:BMEZ) in the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 754,822 shares of the company’s stock, valued at approximately $10,869,000.

Several other institutional investors have also recently bought and sold shares of the business. Brown Brothers Harriman & Co. purchased a new position in BlackRock Health Sciences Term Trust in the third quarter worth $32,000. K2 Principal Fund L.P. purchased a new stake in shares of BlackRock Health Sciences Term Trust during the 3rd quarter valued at approximately $158,000. Jane Street Group LLC bought a new position in shares of BlackRock Health Sciences Term Trust in the third quarter worth $357,000. Kingswood Wealth Advisors LLC purchased a new position in BlackRock Health Sciences Term Trust during the 4th quarter valued at about $420,000. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in BlackRock Health Sciences Term Trust during the fourth quarter valued at approximately $471,000.

BlackRock Health Sciences Term Trust Stock Down 0.3 %

NYSE:BMEZ opened at $15.13 on Friday. BlackRock Health Sciences Term Trust has a twelve month low of $14.27 and a twelve month high of $16.75. The business’s 50-day moving average price is $15.79 and its two-hundred day moving average price is $15.63.

BlackRock Health Sciences Term Trust Dividend Announcement

The firm also recently declared a monthly dividend, which will be paid on Monday, March 31st. Shareholders of record on Friday, March 14th will be paid a $0.1763 dividend. This represents a $2.12 annualized dividend and a yield of 13.98%. The ex-dividend date is Friday, March 14th.

About BlackRock Health Sciences Term Trust

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.